Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Depreciation & Amortization (CF): 2020-2025

Historic Depreciation & Amortization (CF) for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Sep 2025 value amounting to $6.1 million.

  • Mirum Pharmaceuticals' Depreciation & Amortization (CF) rose 0.12% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.2 million, marking a year-over-year increase of 5.02%. This contributed to the annual value of $23.6 million for FY2024, which is 118.20% up from last year.
  • Latest data reveals that Mirum Pharmaceuticals reported Depreciation & Amortization (CF) of $6.1 million as of Q3 2025, which was up 0.10% from $6.1 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $6.1 million in Q3 2025 and a low of $79,000 during Q2 2021.
  • In the last 3 years, Mirum Pharmaceuticals' Depreciation & Amortization (CF) had a median value of $5.9 million in 2024 and averaged $4.8 million.
  • Data for Mirum Pharmaceuticals' Depreciation & Amortization (CF) shows a peak YoY soared of 1,204.76% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Mirum Pharmaceuticals' Depreciation & Amortization (CF) stood at $342,000 in 2021, then surged by 251.17% to $1.2 million in 2022, then skyrocketed by 357.45% to $5.5 million in 2023, then grew by 10.23% to $6.1 million in 2024, then increased by 0.12% to $6.1 million in 2025.
  • Its last three reported values are $6.1 million in Q3 2025, $6.1 million for Q2 2025, and $6.1 million during Q1 2025.